Semax 10mg Canada

Technical Specifications

Compound Name: Semax (Met-Glu-His-Phe-Pro-Gly-Pro)
Quantity: 10mg per vial
Format: Lyophilized peptide powder
Peptide Length: 7 amino acids
Molecular Weight: Approximately 813.9 g/mol
Purity Standard: ≥98% (HPLC, batch dependent)
Research Classification: Investigational peptide – laboratory research use only

Semax 10mg Canada is supplied as a lyophilized synthetic heptapeptide for laboratory and analytical use only. Each vial contains 10 milligrams of the peptide prepared under controlled handling and quality verification standards appropriate for research material distribution.

This product is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada when supplied in research format.

Research Overview

Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–7) with an added Pro-Gly-Pro sequence to enhance stability in experimental systems. It has been studied in neuroscience and neuroendocrine research contexts for its interaction with central nervous system signalling pathways.

Research involving Semax 10mg Canada typically focuses on neurotrophic factor expression, neurotransmitter modulation, and stress-response signalling in laboratory environments. Scientific literature describes Semax as a peptide investigated in experimental models of cognitive function and neural plasticity.

Preclinical studies have evaluated Semax in cell culture and animal models, examining brain-derived neurotrophic factor (BDNF) expression, dopaminergic signalling, and regulation of the glutamatergic pathway. Exploratory clinical research has also been conducted in controlled settings toanalyzee neurophysiological markers.

Semax 10mg Canada is supplied strictly for research purposes. All references to neurological or biochemical pathways reflect investigational findings and do not imply authorized clinical or therapeutic application.

Mechanism Overview

Semax is structurally based on the ACTH 4–7 fragment, a sequence associated with central nervous system activity in laboratory models. The addition of a Pro-Gly-Pro motif enhances resistance to enzymatic degradation in experimental systems.

In research settings, Semax has been studied for its influence on neurotrophic factor expression, particularly BDNF, and for its modulation of monoamine neurotransmitter systems. Laboratory investigations often assesschanges in gene expression, receptor interaction profiles, and electrophysiological responses in neural tissue models.

Semax 10mg Canada is evaluated in controlled environments to measure signalling pathway activation, neuronal survival markers, and synaptic plasticity indicators. Mechanistic descriptions remain confined to preclinical and investigational data and are presented for educational purposes only.

Clinical Development Context

Semax has been developed and studied in certain international research and clinical settings, particularly within Eastern European scientific programmes. Some formulations have been authorized in specific jurisdictions under medical supervision.

However, Semax 10mg, supplied in research-grade format, is categorized as an investigational laboratory compound. It is distinct from authorized pharmaceutical preparations and is not approved by Health Canada for prescription use when provided as a research material.

Academic interest in neuropeptide analogues continues in neuroscience research institutions that study cognitive and stress-related signalling pathways.

Regulatory Status in Canada

Semax 10mg Canada is classified as an investigational research peptide. It is not authorized by Health Canada as a therapeutic drug, natural health product, or over-the-counter medication when supplied in research format.

The peptide is provided exclusively for laboratory and analytical purposes and is not intended for human or veterinary administration.

Handling, storage, and study of Semax 10mg in Canada must comply with applicable federal and provincial Canadian regulations governing chemical and biological research materials. Laboratories and research institutions are responsible for maintaining regulatory compliance.

Molecular and Structural Notes

Semax is a heptapeptide composed of the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro. The Pro-Gly-Pro extension contributes to structural stability and increased resistance to proteolytic degradation in vitro.

The molecular weight of approximately 813.9 g/mol reflects its relatively small peptide structure compared to larger neuropeptides. Its size allows researchers to study minimal peptide motifs that can influence central signalling pathways in laboratory systems.

Semax 10mg Canada is typically characterized using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry to confirm identity and purity before distribution.

The lyophilized format supports peptide stability during storage when maintained under appropriate laboratory conditions.

Frequently Asked Questions

What is Semax 10mg Canada studied for in research?
Semax 10mg Canada is studied in laboratory settings to investigate neurotrophic factor expression and neurotransmitter signalling pathways.

Is Semax approved for medical use in Canada? Health Canada does not authorize research-grade Semax for therapeutic or consumer use.

What type of peptide is Semax?
It is a synthetic, ACTH-derived heptapeptide analogue used in neuroscience research.

Does Semax 10mg Canada contain additives?
Unless specified in the batch documentation, the vial contains only the lyophilized peptide compound.

Can Semax 10mg Canada be used outside research facilities?
No. It is supplied strictly for controlled laboratory and analytical research purposes.

Educational Disclaimer

Semax 10mg Canada is an investigational research peptide supplied solely for laboratory and analytical use. It is not approved by Health Canada as a medication, therapeutic agent, or consumer product when provided in research-grade form.

The information provided on this page is educational and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.

Study and handling of Semax 10mg Canada should occur only within properly equipped research facilities and in accordance with applicable Canadian regulations and institutional guidelines.